why choose us

First received: January 30, 2023

Clinical Trial: Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Renal Cell Carcinoma

Study Type: INTERVENTIONAL


Official Title: Randomized Pilot Clinical Trial of Neoadjuvant Pembrolizumab +/- Lenvatinib for High Risk Renal Cell Carcinoma

Brief Summary: This study will evaluate the effect of investigational drugs, pembrolizumab alone or pembrolizumab with lenvatinib, on the immune systems response to kidney cancer when given before and after surgery to remove kidney cancer.

Read more